<DOC>
	<DOCNO>NCT01984892</DOCNO>
	<brief_summary>The purpose study test safety course injection contain Poly-ICLC patient advance solid tumor easily safely reach needle . Poly-ICLC compound use help body fight cancer .</brief_summary>
	<brief_title>Treatment Solid Tumors With Intratumoral Hiltonol® ( Poly-ICLC )</brief_title>
	<detailed_description>We hypothesize therapeutic in-situ autovaccination strategy comprise three immunomodulatory step . The first innate immune local tumor kill induced intratumoral Hiltonol ( via NK , TNF , etc ) . A close second step optimal Th1-weighted prim in-situ combination poly-ICLC danger signal tumor antigen release step 1 process cross-presented poly-ICLC activate mDC , etc . The repeated administration Hiltonol danger signal IT context patient 's tumor antigens way mimic natural viral infection may critical step . Once system optimally prim , third step target maintenance immune response facilitation remote tumor site IM poly-ICLC chemokine release , inflammasome activation costimulatory factor .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Basal Cell</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>Histologically confirm diagnosis melanoma , squamous head neck cancer , sarcoma , squamous cell carcinoma skin , basal cell skin cancer , breast cancer Sarcoma Patients must @ least14 yrs age ; others 18 yrs age older . Unresectable disease . Patients resectable disease may enrol refuse surgery document consultation surgeon . Disease progress @ least 1 systemic therapy local irradiation within precede 6 mo . Radiologically visually measurable recurrent metastatic disease @ least 10mm long dimension . At least 1 accessible primary metastatic tumor site readily inject IT polyICLC without ultrasound guidance . Lesion superficial cutaneous , subcutaneous within readily accessible lymph node &amp; must measure @ least 10mm long dimension . Tumor site injection irradiate within 8 wks C1D1 ECOG performance status ≤ 2 . Normal hematologic , renal &amp; liver function . INR &lt; 2 anticoagulation . Patients anticoagulation therapy INR &gt; 2 may enrol discretion investigator . Patients able provide inform consent . Must agree follow acceptable birth control method continue @ least 2 mo . last polyICLC dose . Women childbearing potential must ( ) pregnancy test . Serious concurrent infection medical illness . Bulky intracranial metastatic disease shift midline structure progressive brain metastasis . Administration immunotherapy conventional chemotherapy treatment metastatic cancer within 4 wks C1D1 Radiation treatment within 4 wks C1D1 AIDS define CD4 count &lt; 200 context HIV seropositivity chronically take immunosuppressive medication steroid transplant relate medication . Life expectancy &lt; 6 mo .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Autologous Vaccination</keyword>
	<keyword>Intratumoral Injections</keyword>
	<keyword>Intramuscular Injections</keyword>
	<keyword>Advanced Accessible Solid Tumors</keyword>
	<keyword>Poly-ICLC</keyword>
	<keyword>Phase II Clinical Trial</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Autovaccination</keyword>
	<keyword>In Situ</keyword>
	<keyword>Host Targeted Strategy</keyword>
	<keyword>Overall Survival</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Adjuvant</keyword>
</DOC>